SCHEMBL248149

SCHEMBL248149

COc1cc(C)c(S(=O)(=O)Cl)c(C)c1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NMT1 P30419 2/20 0.50
TRPV4 Q9HBA0 1/20 0.42
F2 P00734 2/20 0.41
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.41
KMT2A Q03164 3/20 0.38
AVPR1A P37288 2/20 0.37
EPHX2 P34913 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
NR3C2 P08235 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
ACHE P22303 1/20 0.35
AVPR1B P47901 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24811430 0.86 TRPV4 (0.41) NMT1TRPV4F2TSHRGLA
SCHEMBL27544457 0.86 NMT1 (0.51) NMT1F2TSHRGLAKMT2A
SCHEMBL11655127 0.85 EPHX2 (0.43) NMT1TRPV4TSHRGLAKMT2A
SCHEMBL8295856 0.84 NMT1 (0.50) NMT1F2TSHRGLAKMT2A
SCHEMBL29381119 0.82 NMT1 (0.49) NMT1F2TSHRGLAKMT2A
SCHEMBL10526657 0.82 NMT1 (0.49) NMT1F2TSHRGLAKMT2A
SCHEMBL114242 0.82 NMT1 (0.49) NMT1F2TSHRGLAKMT2A
SCHEMBL3449519 0.82 NMT1 (0.49) NMT1F2TSHRGLAKMT2A
Hydrochloric Acid SCHEMBL640366 0.81 NMT1 (0.48) NMT1F2TSHRGLAKMT2A
SCHEMBL14519877 0.79 NMT1 (0.47) NMT1F2KMT2AAVPR1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
WO-2005037811-A1 A METHOD FOR THE PRODUCTION OF CHIRAL SUBSTITUTED EPOXIDES DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) 2005-04-28 WO claimed
US-4487726-A USED IN SYNTHESIS OF PEPTIDES CONTAINING GAUNIDING GROUP TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1984-12-11 US claimed
JP-2049799-A None JP disclosed
JP-1151549-A None JP disclosed
JP-2015094-A None JP disclosed
JP-1151550-A None JP disclosed
US-11773057-B2 Naphthalenesulfonamide compound, preparation method, and application CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-10-03 US disclosed
EP-3978471-B1 NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION UNIV CHINA PHARMA (CN) 2023-02-22 EP disclosed
US-20220251035-A1 NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION CHINA PHARMACEUTICAL UNIVERSITY (CN) 2022-08-11 US disclosed
EP-3978471-A1 NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION China Pharmaceutical University (CN) 2022-04-06 EP disclosed
EP-0056274-B1 INDOLE DERIVATIVES AND A METHOD FOR PRODUCTION OF PEPTIDES Takeda Chemical Industries, Ltd. (JP) 1984-05-09 EP disclosed
US-4416820-A Indole derivatives and a method for production of peptides TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1983-11-22 US disclosed
EP-0078498-A1 Method for protecting amino group and restoring the same Takeda Chemical Industries, Ltd. (JP) 1983-05-11 EP disclosed
US-4368150-A WITH A BENZENESULFONYL COMPOUND TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1983-01-11 US disclosed
EP-0056274-A1 Indole derivatives and a method for production of peptides Takeda Chemical Industries, Ltd. (JP) 1982-07-21 EP disclosed
EP-0033976-A2 Method for protecting guanidino group and restoring the same Takeda Chemical Industries, Ltd. (JP) 1981-08-19 EP disclosed
JP-H00249799-A 0001-01-01 JP disclosed
JP-H00215094-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773057-B2 Naphthalenesulfonamide compound, preparation method, and application NFE2L2, KEAP1, NFE2 NMT1 394/4885TRPV4 1526/4885F2 2539/4885
US-20220251035-A1 NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION NFE2L2, KEAP1, NFE2 NMT1 394/4885TRPV4 1526/4885F2 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.